Afimetoran (BMS-986256) is an orally active, selective, and highly bioavailable antagonist of Toll-like Receptor 7 and 8 (TLR7/8). It operates by inhibiting the activation of the NF-κB pathway, which is crucial in immune responses. Furthermore, Afimetoran can reverse TLR7-mediated resistance to steroid-induced apoptosis in plasma cell-like dendritic cells (pDCs). This compound is valuable for research into inflammation and autoimmune diseases, such as systemic lupus erythematosus.
- Orally active
- Selective TLR7/8 antagonist
- Highly bioavailable
- Inhibits NF-κB pathway
- Reverses steroid resistance
- Research applications
- Demonstrated in vivo efficacy